| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dfed36b24476481a48b5c967c495b760 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2123-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0482
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0493
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0455 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 |
| filingDate |
2018-09-14^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-08-17^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55d5555ea488a5add8bf250b6c7e413b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c4d1e148c59607ebb84bdbdacce0edb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0876012c0590ee660aa5fa9ebd96e35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8ca7e5b50471d31a9947a9b323bce5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95ce9a9583021e2a800876b1333d0261 |
| publicationDate |
2021-08-17^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11090395-B2 |
| titleOfInvention |
Composition for cross talk between estrogen receptors and cannabinoid receptors |
| abstract |
A composition for cross talk between estrogen receptors and cannabinoid receptors including a chelator and a receptor ligand is provided. A method of synthesizing the composition is also provided, and the composition may be further prepared in pharmaceutical formulations or kits for therapy or molecular imaging. |
| priorityDate |
2018-09-14^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |